Cargando…

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults

BACKGROUND: Two phylogenetic lineages of influenza B virus coexist and circulate in the human population (B/Yamagata and B/Victoria) but only one B-strain is included in each seasonal vaccine. Mismatch regularly occurs between the recommended and circulating B-strain. Inclusion of both lineages in v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beran, Jiří, Peeters, Mathieu, Dewé, Walthère, Raupachová, Jolana, Hobzová, Lenka, Devaster, Jeanne-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668902/ https://www.ncbi.nlm.nih.gov/pubmed/23688546 http://dx.doi.org/10.1186/1471-2334-13-224

Ejemplares similares

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2016)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population
por: Tavares, Diana, et al.
Publicado: (2022)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
por: Langley, Joanne M., et al.
Publicado: (2013)

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013)

A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
por: Carmona Martinez, Alfonso, et al.
Publicado: (2014)

Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies
por: Liu, Xiaoqiang, et al.
Publicado: (2022)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis
por: Bianculli, Pablo Manuel, et al.
Publicado: (2022)

A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age
por: Pavia-Ruz, Noris, et al.
Publicado: (2013)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland
por: Nagy, Lisa, et al.
Publicado: (2016)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
por: You, Joyce HS, et al.
Publicado: (2014)

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines
por: van Essen, Gerrit A, et al.
Publicado: (2014)

Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico
por: Ruiz-Palacios, Guillermo M., et al.
Publicado: (2019)

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017
por: Gaglani, Manjusha, et al.
Publicado: (2020)

Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay
por: Arbo, Antonio, et al.
Publicado: (2022)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
por: Lin, Shin-Yu, et al.
Publicado: (2013)

Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
por: Dolk, Christiaan, et al.
Publicado: (2016)

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™
por: Canelle, Quentin, et al.
Publicado: (2016)

The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia
por: de Boer, Pieter T., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
por: Vesikari, Timo, et al.
Publicado: (2019)

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease
por: Benoit, Anne, et al.
Publicado: (2015)

Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer
por: Kotecha, Rishi S., et al.
Publicado: (2015)

Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach
por: Brogan, Anita J., et al.
Publicado: (2016)

Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil – comparison of outcomes from different static model types
por: Van Bellinghen, Laure-Anne, et al.
Publicado: (2018)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
por: Hu, Yuemei, et al.
Publicado: (2019)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

Safety and immunogenicity of 3 seasonal trivalent influenza vaccines in the Chinese military
por: Gao, Dongqi, et al.
Publicado: (2016)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
por: Milne, George J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kv41nt5osb0kkhaj6mr2o6ehiu